Navigation Links
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Date:12/22/2009

SAN DIEGO, Dec. 22, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer, stated, "Physicians need new, better-tolerated approaches to improve the treatment of patients who are obese or significantly overweight. Based on the robust data package we submitted to the FDA, lorcaserin has the potential to meet this need, offering patients the opportunity to achieve sustainable weight loss in a well-tolerated manner and improve their cardiometabolic health and quality of life."

The pivotal Phase 3 clinical trial program, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), evaluated nearly 7,200 patients treated for up to two years and showed that lorcaserin consistently produced significant weight loss with excellent safety and tolerability.

"Today's NDA submission is an important milestone towards realizing lorcaserin's significant commercial potential, and we are excited by the possibility of bringing lorcaserin to patients who need help in managing their weight," said Jack Lief, Arena's President and Chief Executive Officer. "Physician feedback suggests that, if approved, lorcaserin's combination of efficacy, safety and tolerability will position the drug candidate a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Lazarus Effect, a medical device company focused ... facilitate removal of blood clots, announced today that ... issued a new patent (U.S. Patent Number 8,795,305) ... TM and ReCover TM devices. ... stent-retriever (stentriever) with an integrated, novel, cover-based protection ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
...  Medtronic, Inc, one of the world,s largest medical device ... U.S. Department of Justice (DOJ), the Office of the ... Services, and four relators in a qui tam suit ... in the U.S., including pacemakers and implantable cardioverter defibrillators ...
... A three-drug combination treatment for the blood cancer multiple myeloma ... patients, according to a multi-center study led by Andrzej ... the multiple myeloma program at the University of Chicago Medical ... of the phase I-II study on Dec. 12, 2011, ...
Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 3
(Date:7/24/2014)... for head and neck cancer (HNC). Evidence suggests certain cancers ... of HNC in patients with DM has not been well ... common type of cancer. It accounts for about 6 percent ... cases and 350,000 cancer deaths worldwide each year. , The ... the risk of HNC in patients with DM. The authors ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
(Date:7/24/2014)... two or more equally positive outcomes experience paradoxical ... activity in different regions of the brain, according ... research scholar at the Princeton Neuroscience Institute at ... people rated the desirability of more than 300 ... at images of paired products with different or ...
(Date:7/24/2014)... Memantine was initially developed by Merz to ... under the brand name Akatinol; it was later licensed to ... in the USA to Forest Labs as Namenda. Lundbeck reported ... In the US, Forest reported Namenda sales of USD 1.5 ... Australia and the European region has increased the competition from ...
(Date:7/24/2014)... at Carnegie Mellon University, working with high-throughput data ... National Laboratory, have devised a computational method to ... breast cells turn malignant and as they respond ... analyzing how genes interact with each other in ... today by the online journal PLOS Computational ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... ... undergoing leg amputation and detect heart disease earlier if diagnosis and treatment ... legs) were given higher priority by the NHS and there was better ... and Wales, the majority of which are caused by PAD, but there ...
... - Breast cancer patients with early stage disease that has ... radiation after mastectomy, because of the low present-day risk of ... could one day change the course of treatment for thousands ... University of Texas M. D. Anderson Cancer. The research, ...
... ... Sayer looked around for a good, reliable manufacturer for her award-winning cloth diapers, she did ... manufacturing facility, she also discovered a great way for her company to support its community ... Calgary, Alberta, Canada (PRWEB) ...
... may be the culprits, researchers suggest, , FRIDAY, March 5 ... red meat is a risk factor for heart disease, but ... meat -- not unprocessed red meat -- that increases the ... "processed meat" refers to any meat preserved by smoking, curing ...
... ... ... , ... , , , , ...
... ... ... ... ...
Cached Medicine News:Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 2Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 3Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 2Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 3Health News:Ecobumz Diapers are Going Green While Investing in its Own Community and Employing Women Looking to Enter or Re-enter the Workplace 2Health News:Processed Meat May Harm the Heart 2Health News:Processed Meat May Harm the Heart 3Health News:Processed Meat May Harm the Heart 4Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 2Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 3Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3
Jewelers Forceps, delicate, straight....
Forceps, pointed, short jaws, suitable for epilation....
Cilia Forceps, slanted jaws, gold plated....
Accurate implant size. Polyoxymethylene (POM)....
Medicine Products: